1. Gelsemine has antitumor activity.
2. Gelsemine has anti-oxidative activity.
3. Gelsemine has anti-hyperlipidemic activity.
4. Gelsemine has marked antinociception in inflammatory, neuropathic and bone cancer pains without inducing antinociceptive tolerance.
1. Rosmarinic acid has antiviral, antibacterial, antiinflammatory and antioxidant activities.
2. Rosmarinic acid is used to treat peptic ulcers, arthritis, cataract, cancer, rheumatoid arthritis and bronchial asthma.
3. Rosmarinic acid is used for food preservation.
4. Rosmarinic acid has potent anticancer, anti-lipid peroxidative and apoptotic effect in 7,12-dimethylbenz(a)anthracene (DMBA) -induced skin carcinogenesis.
5. Rosmarinic acid mediates neuroprotective effects against H2O2-induced neuronal cell damage in N2A cells, suggests that it may potentially serve as an agent for prevention of several human neurodegenerative diseases caused by oxidative stress.
1. Koumine can induce apoptosis of LoVo cells in a time-dependent manner and inhibit the DNA synthesis in LoVo cells, thereby blocking the cell cycle from G1 to S phase.
2. Koumine has a significant analgesic effect in rodent behavioral models of inflammatory and neuropathic pain, and that the reduction in neuropathic pain may be associated with the upregulation of allopregnanolone in the spinal cord.
3. Koumine has therapeutic effect against psoriasis, which is related to the inhibition of epidermal cell proliferation, promoting the formation of granular cells and decreasing the serum level of IL-2.
4. Koumine can significantly reduce the damage to axon and myelin sheath of the sciatic nerve and increase sensory nerve conduction velocity , without affecting body weight and blood glucose, these findings encourage the use of koumine in the treatment of diabetic neuropathy.
5. Koumine has antineoplastic effect, may be a future breast cancer chemotherapeutic agent.
6. Koumine may produce anxiolytic-effect by increasing the levels of pregnenolone and allopregnenolone in hippocampus.
1. Cannabidiol can reduce the anxiety provoked by Delta-9-tetrahydrocannabinol (delta-9-THC) in normal volunteers, and the effects of cannabidiol , as opposed to those of delta 9-THC, may be involved in the antagonism of effects between the two cannabinoids.
2. Cannabidiol has a potent anti-arthritic effect in collagen-induced arthritis through its combined immunosuppressive and anti-inflammatory actions.
3. Cannabidiol has a pharmacological profile similar to that of atypical antipsychotic drugs.
4. Cannabidiol is a potent inhibitor of cancer cell growth (IC50 between 6.0 and 10.6 microM), with significantly lower potency in noncancer cells.
5. Cannabidiol exerts a combination of neuroprotective, anti-oxidative and anti-apoptotic effects against beta-amyloid peptide toxicity, and that inhibition of caspase 3 appearance from its inactive precursor, pro-caspase 3, by cannabidiol is involved in the signalling pathway for this neuroprotection.
6. Cannabidiol may have great therapeutic potential in the treatment of diabetic complications, and perhaps other cardiovascular disorders, by attenuating oxidative/ nitrative stress, inflammation, cell death and fibrosis.
1. Danshensu has antioxidant activity, can enhance HO-1 expression to suppress 6-OHDA-induced oxidative damage via PI3K/Akt/Nrf2 signaling pathways.
2. Danshensu has neuroprotective activity, can reduce 6-OHDA-induced dopaminergic neuronal loss in zebrafish.
3. Danshensu has anxiolytic-like properties, in part, through dopaminergic neurotransmitter signaling.
4. Danshensu has cardioprotective effect, can treat cardiovascular diseases.
5. Chronic treatment with danshensu can prevent/attenuate the formation of atherosclerosis, the potential mechanisms include inhibited expression of representative proinflammatory cytokines and adhesion molecules in arterial endothelia, and changes in homocysteine and circulating molecules that control vascular contraction/relaxation via endothelial cells (eg, endothelin and NO).